The Role of Complement, C5a and Its Receptors in Sepsis and Multiorgan Dysfunction Syndrome

REFERENCES

• Angus D C, Linde-Zwirble W T, Lidicker J, Clermont G, Carcillo J, Pinsky M R. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303–1310, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Martin G S, Mannino D M, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546–1554, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bone R C, Fisher C J, Jr., Clemmer T P, Slotman G J, Metz C A, Balk R A. Sepsis syndrome: A valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989; 17: 389–393, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Goris R J, te Boekhorst T P, Nuytinck J K, Gimbrere J S. Multiple-organ failure. Generalized autodestructive inflammation?. Arch Surg 1985; 120: 1109–1115, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nuytinck H K, Offermans X J, Kubat K, Goris J A. Whole-body inflammation in trauma patients. An autopsy study. Arch Surg 1988; 123: 1519–1524, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bone R C, Sprung C L, Sibbald W J. Definitions for sepsis and organ failure. Crit Care Med 1992; 20: 724–726, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bone R C, Balk R A, Cerra F B, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine, 1992; 101: 1644–1655, Chest
   Google Scholar
• Guo R F, Ward P A. Role of C5a in inflammatory responses. Annu Rev Immunol 2005; 23: 821–852, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Riedemann N C, Guo R F, Ward P A. The enigma of sepsis. J Clin Invest 2003; 112: 460–467, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ward P A. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 4: 133–142, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Muller-Eberhard H J. Molecular organization and function of the complement system. Annu Rev Biochem 1988; 57: 321–347, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Reid K B, Porter R R. The proteolytic activation systems of complement. Annu Rev Biochem 1981; 50: 433–464, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol 2002; 2: 346–353, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dempsey P W, Vaidya S A, Cheng G. The art of war: Innate and adaptive immune responses. Cell Mol Life Sci 2003; 60: 2604–2621, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Huber-Lang M, Younkin E M, Sarma J V, et al. Generation of C5a by phagocytic cells. Am J Pathol 2002; 161: 1849–1859, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gerard C. Complement C5a in the sepsis syndrome—Too much of a good thing?. N Engl J Med 2003; 348: 167–169, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Smedegard G, Cui L X, Hugli T E. Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol 1989; 135: 489–497, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Czermak B J, Sarma V, Pierson C L, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999; 5: 788–792, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Huber-Lang M S, Riedeman N C, Sarma J V, et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002; 16: 1567–1574, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Huber-Lang M S, Sarma J V, McGuire S R, et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 2001; 15: 568–570, [INFOTRIEVE], [CSA]
   Google Scholar
• Huber-Lang M, Sarma V J, Lu K T, et al. Role of C5a in multiorgan failure during sepsis. J Immunol 2001; 166: 1193–1199, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nakae H, Endo S, Inada K, Takakuwa T, Kasai T, Yoshida M. Serum complement levels and severity of sepsis. Res Commun Chem Pathol Pharmacol 1994; 84: 189–195, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Nakae H, Endo S, Inada K, Yoshida M. Chronological changes in the complement system in sepsis. Surg Today 1996; 26: 225–229, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stove S, Welte T, Wagner T O, et al. Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 1996; 3: 175–183, [INFOTRIEVE], [CSA]
   Google Scholar
• Hack C E, Nuijens J H, Felt-Bersma R J, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989; 86: 20–26, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gardinali M, Padalino P, Vesconi S, et al. Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Correlation with severity of disease. Arch Surg 1992; 127: 1219–1224, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Horstick G, Kempf T, Lauterbach M, et al. C1-esterase-inhibitor treatment at early reperfusion of hemorrhagic shock reduces mesentry leukocyte adhesion and rolling. Microcirculation 2001; 8: 427–433, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit Care Med 1999; 27: 597–604, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fischer M B, Prodeus A P, Nicholson-Weller A, et al. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol 1997; 159: 976–982, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zeerleder S, Caliezi C, van Mierlo G, et al. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol 2003; 10: 529–535, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Caliezi C, Zeerleder S, Redondo M, et al. C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction. Crit Care Med 2002; 30: 1722–1728, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kildsgaard J, Hollmann T J, Matthews K W, Bian K, Murad F, Wetsel R A. Cutting edge: Targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol 2000; 165: 5406–5409, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Boos L, Szalai A J, Barnum S R. C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci Lett 2005; 387: 68–71, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Sacks T, Moldow C F, Craddock P R, Bowers T K, Jacob H S. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest 1978; 61: 1161–1167, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shin H S, Snyderman R, Friedman E, Mellors A, Mayer M M. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science 1968; 162: 361–363, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Goldstein I M, Weissmann G. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol 1974; 113: 1583–1588, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schumacher W A, Fantone J C, Kunkel S E, Webb R C, Lucchesi B R. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions 1991; 34: 345–349, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Chenoweth D E, Hugli T E. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978; 75: 3943–3947, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gerard N P, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991; 349: 614–617, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fureder W, Agis H, Willheim M, et al. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol 1995; 155: 3152–3160, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zwirner J, Gotze O, Begemann G, Kapp A, Kirchhoff K, Werfel T. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 1999; 97: 166–172, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Osaka H, McGinty A, Hoepken U E, Lu B, Gerard C, Pasinetti G M. Expression of C5a receptor in mouse brain: Role in signal transduction and neurodegeneration. Neuroscience 1999; 88: 1073–1082, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Gasque P, Singhrao S K, Neal J W, Gotze O, Morgan B P. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997; 150: 31–41, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fayyazi A, Scheel O, Werfel T, et al. The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology 2000; 99: 38–45, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Zwirner J, Fayyazi A, Gotze O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999; 36: 877–884, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Schlaf G, Schieferdecker H L, Rothermel E, Jungermann K, Gotze O. Differential expression of the C5a receptor on the main cell types of rat liver as demonstrated with a novel monoclonal antibody and by C5a anaphylatoxin-induced Ca2+ release. Lab Invest 1999; 79: 1287–1297, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Braun M, Davis A E, 3rd. Cultured human glomerular mesangial cells express the C5a receptor. Kidney Int 1998; 54: 1542–1549, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Mollison K W, Mandecki W, Zuiderweg E R, et al. Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc Natl Acad Sci USA 1989; 86: 292–296, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Zuiderweg E R, Nettesheim D G, Mollison K W, Carter G W. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry 1989; 28: 172–185, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Huber-Lang M S, Sarma J V, McGuire S R, et al. Structure–function relationships of human C5a and C5aR. J Immunol 2003; 170: 6115–6124, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Siciliano S J, Rollins T E, DeMartino J, et al. Two-site binding of C5a by its receptor: An alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994; 91: 1214–1218, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cain S A, Monk P N. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J Biol Chem 2002; 277: 7165–7169, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi T A. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol 2000; 37: 407–412, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lee D K, George S R, Cheng R, et al. Identification of four novel human G protein-coupled receptors expressed in the brain. Brain Res Mol Brain Res 2001; 86: 13–22, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kalant D, Cain S A, Maslowska M, Sniderman A D, Cianflone K, Monk P N. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J Biol Chem 2003; 278: 11123–11129, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Okinaga S, Slattery D, Humbles A, et al. C5L2, a nonsignaling C5A binding protein. Biochemistry 2003; 42: 9406–9415, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Solomkin J S, Jenkins M K, Nelson R D, Chenoweth D, Simmons R L. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery 1981; 90: 319–327, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Guo R F, Riedemann N C, Bernacki K D, et al. Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J 2003; 17: 1889–1891, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Furebring M, Hakansson L D, Venge P, Nilsson B, Sjolin J. Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care 2002; 6: 363–370, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Seely A J, Naud J F, Campisi G, et al. Alteration of chemoattractant receptor expression regulates human neutrophil chemotaxis in vivo. Ann Surg 2002; 235: 550–559, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Strieter R M, Kasahara K, Allen R M, et al. Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol 1992; 141: 397–407, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hopken U, Mohr M, Struber A, et al. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol 1996; 26: 1103–1109, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Laudes I J, Chu J C, Huber-Lang M, et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002; 169: 5962–5970, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Riedemann N C, Guo R F, Sarma V J, et al. Expression and function of the C5a receptor in rat alveolar epithelial cells. J Immunol 2002; 168: 1919–1925, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Monsinjon T, Gasque P, Chan P, Ischenko A, Brady J J, Fontaine M C. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17: 1003–1014, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Riedemann N C, Guo R F, Neff T A, et al. Increased C5a receptor expression in sepsis. J Clin Invest 2002; 110: 101–108, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fukuoka Y, Strainic M, Medof M E. Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a. Clin Exp Immunol 2003; 131: 248–253, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Huber-Lang M, Sarma J V, Rittirsch D, et al. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J Immunol 2005; 174: 1104–1110, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gao H, Neff T A, Guo R F, et al. Evidence for a functional role of the second C5a receptor C5L2. FASEB J 2005; 19: 1003–1005, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Huber-Lang M S, Younkin E M, Sarma J V, et al. Complement-induced impairment of innate immunity during sepsis. J Immunol 2002; 169: 3223–3231, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zaitsu M, Hamasaki Y, Matsuo M, et al. New induction of leukotriene A(4) hydrolase by interleukin-4 and interleukin-13 in human polymorphonuclear leukocytes. Blood 2000; 96: 601–609, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Guo R F, Riedemann N C, Ward P A. Role of C5a–C5aR interaction in sepsis. Shock 2004; 21: 1–7, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Reinhart K, Bloos F, Brunkhorst F M. Pathophysiology of Sepsis and Multiple Organ Dysfunction, 5th ed. Elsevier, Philadelphia 2005
   Google Scholar
• Bone R C, Grodzin C J, Balk R A. Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235–243, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Levy M M, Fink M P, Marshall J C, et al (2003) SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. 2001. 31: 1250–1256, Crit Care Med
   Google Scholar
• Goya T, Morisaki T, Torisu M. Immunologic assessment of host defense impairment in patients with septic multiple organ failure: Relationship between complement activation and changes in neutrophil function. Surgery 1994; 115: 145–155, [INFOTRIEVE], [CSA]
   Google Scholar
• Niederbichler A D, Hoesel L M, Westfall M V, et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 2006; 203: 53–61, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Roumen R M, Redl H, Schlag G, et al. Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma. Crit Care Med 1995; 23: 474–480, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Bengtson A, Heideman M. Anaphylatoxin formation in sepsis. Arch Surg 1988; 123: 645–649, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Heideman M, Norder-Hansson B, Bengtson A, Mollnes T E. Terminal complement complexes and anaphylatoxins in septic and ischemic patients. Arch Surg 1988; 123: 188–192, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bengtson A, Haljamae H. Complement activation and organ function in critically ill surgical patients. Acute Care 1988; 14–15: 111–137, [CSA]
   Google Scholar
• Zimmermann T, Laszik Z, Nagy S, Kaszaki J, Joo F. The role of the complement system in the pathogenesis of multiple organ failure in shock. Prog Clin Biol Res 1989; 308: 291–297, [INFOTRIEVE], [CSA]
   Google Scholar
• Helliwell T R, Wilkinson A, Griffiths R D, Palmer T E, McClelland P, Bone J M. Microvascular endothelial activation in the skeletal muscles of patients with multiple organ failure. J Neurol Sci 1998; 154: 26–34, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Bengtson A, Heideman M. Altered anaphylatoxin activity during induced hypoperfusion in acute and elective abdominal aortic surgery. J Trauma 1986; 26: 631–637, [INFOTRIEVE], [CSA]
   Google Scholar
• Heideman M, Hugli T E. Anaphylatoxin generation in multisystem organ failure. J Trauma 1984; 24: 1038–1043, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Seghaye M C, Duchateau J, Grabitz R G, et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. J Thorac Cardiovasc Surg 1993; 106: 978–987, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Slutsky A S. Hot new therapy for sepsis and the acute respiratory distress syndrome. J Clin Invest 2002; 110: 737–739, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar